PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Cost reduction while AGEN shows 35729.57% growth. Joel Greenblatt would examine competitive advantage.
100.00%
Positive growth while AGEN shows decline. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
10.75%
Similar R&D growth to AGEN's 11.66%. Walter Schloss would investigate industry innovation requirements.
-21.32%
G&A reduction while AGEN shows 2.73% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.47%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
1.47%
Total costs growth less than half of AGEN's 5.43%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
6.88%
D&A growth while AGEN reduces D&A. John Neff would investigate differences.
-1.39%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-1.47%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-3.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-1.89%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.89%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
2.63%
EPS growth while AGEN declines. John Neff would investigate advantages.
2.63%
Diluted EPS growth while AGEN declines. John Neff would investigate advantages.
3.22%
Share count reduction below 50% of AGEN's 2.32%. Michael Burry would check for concerns.
3.22%
Diluted share reduction below 50% of AGEN's 2.32%. Michael Burry would check for concerns.